Format
Sort by
Items per page

Send to

Choose Destination

Links from PubMed

Items: 1 to 20 of 101

1.

Comparing the cost effectiveness of risperidone and olanzapine in the treatment of schizophrenia using the net-benefit regression approach.

De Ridder A, De Graeve D.

Pharmacoeconomics. 2009;27(1):69-80. doi: 10.2165/00019053-200927010-00007.

PMID:
19178125
2.

[Cost-effectiveness analysis of schizophrenic patient care settings: impact of an atypical antipsychotic under long-acting injection formulation].

Llorca PM, Miadi-Fargier H, Lançon C, Jasso Mosqueda G, Casadebaig F, Philippe A, Guillon P, Mehnert A, Omnès LF, Chicoye A, Durand-Zaleski I.

Encephale. 2005 Mar-Apr;31(2):235-46. Review. French.

PMID:
15959450
3.

Long-acting risperidone compared with oral olanzapine and haloperidol depot in schizophrenia: a Belgian cost-effectiveness analysis.

De Graeve D, Smet A, Mehnert A, Caleo S, Miadi-Fargier H, Mosqueda GJ, Lecompte D, Peuskens J.

Pharmacoeconomics. 2005;23 Suppl 1:35-47.

PMID:
16416760
4.

Pharmacy cost evaluation of risperidone, olanzapine, and quetiapine for the treatment of schizophrenia in acute care inpatient settings.

Mladsi DM, Grogg AL, Irish WD, Lopez RB, Degen K, Swann A, Nimsch CT.

Curr Med Res Opin. 2004 Dec;20(12):1883-93.

PMID:
15701206
5.

Risperidone compared with olanzapine in a naturalistic clinical study in Ireland: a cost analysis.

Lucey JV, Libretto SE.

Ir J Med Sci. 2003 Oct-Dec;172(4):195-201.

PMID:
15029989
6.

A population-based cost-effectiveness analysis of olanzapine and risperidone among ambulatory patients with schizophrenia.

Cooper D, Moisan J, Abdous B, Grégoire JP.

Can J Clin Pharmacol. 2008 Fall;15(3):e385-97. Epub 2008 Oct 24.

PMID:
18953083
7.

Cost of antipsychotic polypharmacy in the treatment of schizophrenia.

Zhu B, Ascher-Svanum H, Faries DE, Correll CU, Kane JM.

BMC Psychiatry. 2008 Apr 4;8:19. doi: 10.1186/1471-244X-8-19.

8.

Cost-utility analysis of treatment with olanzapine compared with other antipsychotic treatments in patients with schizophrenia in the pan-European SOHO study.

Knapp M, Windmeijer F, Brown J, Kontodimas S, Tzivelekis S, Haro JM, Ratcliffe M, Hong J, Novick D; SOHO Study Group.

Pharmacoeconomics. 2008;26(4):341-58.

PMID:
18370568
9.

Association of co-morbidities with prescribing patterns and cost savings: olanzapine versus risperidone for schizophrenia.

Yu W, Ren XS, Lee AF, Herz L, Huang YH, Kazis LE.

Pharmacoeconomics. 2006;24(12):1233-48.

PMID:
17129077
10.

Effectiveness and cost of risperidone and olanzapine for schizophrenia: a systematic review.

Hargreaves WA, Gibson PJ.

CNS Drugs. 2005;19(5):393-410. Review. Erratum in: CNS Drugs. 2005;19(9):784. Gibson, Joseph P [corrected to Gibson, P Joseph].

PMID:
15907151
11.

The impact of olanzapine, risperidone, or haloperidol on the cost of schizophrenia care in a medicaid population.

Gibson PJ, Damler R, Jackson EA, Wilder T, Ramsey JL.

Value Health. 2004 Jan-Feb;7(1):22-35.

12.

Risperidone compared with olanzapine in a naturalistic clinical study: a cost analysis.

Taylor DM, Wright T, Libretto SE; Risperidone Olanzapine Drug Outcomes Studies in Schizophrenia (RODOS) U.K. Investigator Group.

J Clin Psychiatry. 2003 May;64(5):589-97.

PMID:
12755664
13.

Cost-effectiveness analysis of olanzapine and risperidone in Norway.

Kim K, Aas E.

J Ment Health Policy Econ. 2011 Sep;14(3):125-35.

PMID:
22116170
14.

Olanzapine versus risperidone in the treatment of schizophrenia : a comparison of costs among Texas Medicaid recipients.

Rascati KL, Johnsrud MT, Crismon ML, Lage MJ, Barber BL.

Pharmacoeconomics. 2003;21(10):683-97.

PMID:
12828491
15.
16.

Assessing cost-effectiveness of drug interventions for schizophrenia.

Magnus A, Carr V, Mihalopoulos C, Carter R, Vos T.

Aust N Z J Psychiatry. 2005 Jan-Feb;39(1-2):44-54.

PMID:
15660705
17.
18.

Cost-effectiveness of olanzapine as first-line treatment for schizophrenia: results from a randomized, open-label, 1-year trial.

Tunis SL, Faries DE, Nyhuis AW, Kinon BJ, Ascher-Svanum H, Aquila R.

Value Health. 2006 Mar-Apr;9(2):77-89.

19.

Cost effectiveness of long-acting risperidone injection versus alternative antipsychotic agents in patients with schizophrenia in the USA.

Edwards NC, Locklear JC, Rupnow MF, Diamond RJ.

Pharmacoeconomics. 2005;23 Suppl 1:75-89.

PMID:
16416763
20.

Cost effectiveness of paliperidone palmitate versus risperidone long-acting injectable and olanzapine pamoate for the treatment of patients with schizophrenia in Sweden.

Mehnert A, Nicholl D, Pudas H, Martin M, McGuire A.

J Med Econ. 2012;15(5):844-61. doi: 10.3111/13696998.2012.681531. Epub 2012 Apr 26.

PMID:
22458756

Supplemental Content

Support Center